1. Generics Bulletin

Three biosimilars are recommended to PBS

 
• By Dean Rudge

Australia’s Pharmaceutical Benefit Advisory Committee (PBAC) has recommended ‘a-flagging’, or marking as equivalent and substitutable at the point of dispensing, two biosimilars of Humira (adalimumab) and one of Lantus (insulin glargine).

Australia’s Pharmaceutical Benefit Advisory Committee (PBAC) has recommended ‘a-flagging’, or marking as equivalent and substitutable at the point of dispensing, two biosimilars of Humira (adalimumab) and one of Lantus (insulin glargine).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 
• By Urtė Fultinavičiūtė

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.